Influence of miR-155 on behaviors of depression mice through regulating Wnt/β-catenin signaling pathway

被引:25
作者
Dai, J. [1 ,2 ]
Pan, J-Y [1 ]
Liao, N. [3 ]
Shi, J. [2 ]
Zeng, Q. [2 ]
Huang, L. [2 ]
Chen, L-P [2 ]
机构
[1] Jinan Univ, Affiliated Hosp 1, Dept Psychiat, Guangzhou, Peoples R China
[2] Peoples Hosp Guangxi Zhuang Autonomous Reg, Nanning, Peoples R China
[3] Guangxi Med Univ, Coll Stomatol, Nanning, Peoples R China
关键词
MiR-155; Depression; Neuroinflammation; INVOLVEMENT; SYMPTOMS; DELIVERY; BDNF;
D O I
10.26355/eurrev_202002_20197
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To study the influence of micro ribonucleic acid (miR)-155 on depression-like behaviors of depression mice, and to explore the role of Wnt/beta-catenin signaling pathway in behavioral regulation of depression mice. MATERIALS AND METHODS: The mouse model of depression was established via chronic unpredictable mild stress (CUMS). All mice were randomly divided into control group (n=12), model group (n=12), and fluoxetine group (n=12). The expression level of miR-155 in the hippocampus of mice in each group was detected via quantitative Polymerase Chain Reaction (qPCR). The changes in the behaviors of mice in each group were evaluated via behavioral experiments. The apoptosis level in the hippocampus of mice in each group was detected via terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining. Moreover, the content of inflammatory factors in the hippocampus of mice in each group was detected using the enzyme-linked immunosorbent assay (ELISA) kits. The expression levels of Wnt/beta-catenin signaling pathway-related proteins in each group were detected via Western blotting. RESULTS: The expression level of miR-155 in the hippocampus was significantly higher in model group than that in control group (p<0.01). Meanwhile. the expression level of miR-155 was significantly lower in fluoxetine group than that in model group (p<0.01). There were no statistically significant differences in the crossing score and rearing score in the open field test among groups (p>0.05). Compared with those in control group, the immobility time in tail suspension test and forced swimming test were significantly increased (p<0.01), while the sucrose preference degree significantly declined (p<0.01) in model group. Fluoxetine could significantly reduce the immobility time in tail suspension test and forced swimming test (p<0.01) and increase the sucrose preference degree (p<0.01) in model group. The number of TUNEL-positive cells in the hippocampus of mice in model group was significantly larger than that in control group (p<0.01). Fluoxetine could effectively reduce the number of TUNEL-positive cells in the hippocampus (p<0.01). Compared with those in control group, the content of tumor necrosis factor-a (TNF-alpha), interleukin-1 beta (IL-1 beta), and IL-6 in the hippocampus was significantly increased (p<0.01), while the content of IL-10 was significantly decreased (p<0.01) in model group. Fluoxetine could effectively reduce the content of TNF-alpha, IL-1 beta, and IL-6 (p<0.01) and increase the content of IL-10 (p<0.01). Besides. in model group, the expression levels of dishevelled-1 (DVL-1) and beta-catenin in hippocampus remarkably declined (p<0.01), while the expression levels of glycogen synthase kinase-3 beta (GSK-3 beta) and adenomatous polyposis coli (APC) were remarkably increased (p<0.01) compared with those in control group. Fluoxetine could effectively lower the expressions of GSK-3 beta and APC in the hippocampus (p<0.01) and increase the expressions of DVL-1 and beta-catenin (p<0.01) in model group. CONCLUSIONS: MiR-155 is involved in regulating the depression-like behaviors of depression mice through promoting the release of inflammatory factors and the apoptosis of hippocampal neurons. Its mechanism may be related to the inhibition of the Wnt/beta-catenin signaling pathway.
引用
收藏
页码:1398 / 1407
页数:10
相关论文
共 20 条
  • [1] Central monoamines and their role in major depression
    Elhwuegi, AS
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2004, 28 (03) : 435 - 451
  • [2] The association between somatic symptoms and suicidal ideation in Chinese first-episode major depressive disorder
    Fang Xinyu
    Zhang Chen
    Wu Zhiguo
    Peng Daihui
    Xia Weiping
    Xu Jingjing
    Wang Chenglei
    Cui Lvchun
    Huang Jia
    Fang Yiru
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2019, 245 : 17 - 21
  • [3] Fernandes MA, 2018, REV BRAS ENFERM, V71, P2169
  • [4] The serotonin-BDNF duo: Developmental implications for the vulnerability to psychopathology
    Homberg, Judith Regina
    Molteni, Raffaella
    Calabrese, Francesca
    Riva, Marco A.
    [J]. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2014, 43 : 35 - 47
  • [5] In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer sternness and metastasis
    Li, Yunfei
    Xiao, Yajuan
    Lin, Hsuan-Pei
    Reichel, Derek
    Bae, Younsoo
    Lee, Eun Y.
    Jiang, Yiguo
    Huang, Xuefei
    Yang, Chengfeng
    Wang, Zhishan
    [J]. BIOMATERIALS, 2019, 188 : 160 - 172
  • [6] Computerized cognitive training in young adults with depressive symptoms: Effects on mood, cognition, and everyday functioning
    Motter, Jeffrey N.
    Grinberg, Alice
    Lieberman, Dahlia H.
    Iqnaibi, Waseem B.
    Sneed, Joel R.
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2019, 245 : 28 - 37
  • [7] Inflammation-associated miR-155 activates differentiation of muscular satellite cells
    Onodera, Yuta
    Teramura, Takeshi
    Takehara, Toshiyuki
    Itokazu, Maki
    Mori, Tatsufumi
    Fukuda, Kanji
    [J]. PLOS ONE, 2018, 13 (10):
  • [8] PATEL KR, 2017, J AM ACAD DERMATOL, V45, P420
  • [9] Decreased BDNF and TrkB mRNA expression in multiple cortical areas of patients with schizophrenia and mood disorders
    Ray, M. T.
    Weickert, C. Shannon
    Webster, M. J.
    [J]. TRANSLATIONAL PSYCHIATRY, 2014, 4 : e389 - e389
  • [10] Neuroendocrinological mechanisms of actions of antidepressant drugs
    Schuele, C.
    [J]. JOURNAL OF NEUROENDOCRINOLOGY, 2007, 19 (03) : 213 - 226